Noruega -
norueguês -
Statens legemiddelverk
nootropil 1200 mg
orifarm as - piracetam - tablett, filmdrasjert - 1200 mg
Noruega -
norueguês -
Statens legemiddelverk
cyramza 10 mg/ ml
orifarm as - ramucirumab - konsentrat til infusjonsvæske, oppløsning - 10 mg/ ml
Noruega -
norueguês -
Statens legemiddelverk
nanocis 0.15 mg
cis bio international - rheniumsulfid - injeksjonsvæske, oppløsning - 0.15 mg
União Europeia -
norueguês -
EMA (European Medicines Agency)
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidemiene - lipid modifiserende midler - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
União Europeia -
norueguês -
EMA (European Medicines Agency)
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).